Acute COVID-19 does not affect corneal sensitivity, study finds

Article

Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

Acute COVID-19 does not affect corneal sensitivity, study finds

Brazilian researchers reported recently that the corneal esthesiometry findings did not differ significantly between patients who had positive and negative polymerase chain reaction (PCR) results for COVID-19, indicating that the acute infection did not impact the ability to obtain reliable test results.1

A team of investigators, led by Dr Lucas Baldissera Tochetto from the Department of Ophthalmology and Visual Science at Federal University of Sao Paulo in Sao Paulo, Brazil, reported their results in the British Journal of Ophthalmology.

A number of ocular manifestations of COVID-19 have previously been reported, and Dr Tochetto pointed out that SARS-CoV-2 RNA was found in the tear film or conjunctival swabs in patients tested using PCR.2 Based on that, the investigators theorized that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

A total of 202 individuals who were suspected of having COVID-19 based on symptomatology participated in this cross-sectional study. All subjects underwent testing for SARS-CoV-2 by nasopharyngeal reverse-transcription qualitative PCR.

All patients also underwent corneal esthesiometry measurements using the Cochet-Bonnet esthesiometer (Luneau Ophthalmologie) during their first visit and the measurements were analyzed based on the findings, presence of anosmia and dysgeusia, and ocular signs and symptoms, Dr Tochetto said.

PCR testing and corneal sensitivity

PCR identified COVID-19 infections in 101 subjects (50%). The mean corneal esthesiometry findings based on the PCR results did not differ significantly when the baseline and first follow-up visit were compared, demonstrating that the virus did not affect the corneal esthesiometry in individuals with acute-phase COVID-19. The mean time from symptom onset to disease diagnosis and corneal esthesiometry was 4.2 days, he noted.

Fifty of the patients who tested positive for COVID-19 also were examined a second time. The mean time between the first to second visits was 32.5 days. The mean respective corneal esthesiometry measurements in the right eye at the 2 evaluations were 5.52 and 5.60 (p=0.616) and for the left eye 5.40 and 5.58 (p=0.173).

The authors concluded that their results indicated that the SARS-CoV-2 infection did not interfere with corneal esthesiometry, at least, in the mild and early stages of this disease.

References
1. Baldissera Tochetto L, de Freitas Santoro D, Hirai F, et al. Impact of COVID-19 on corneal esthesiometry. Br J Ophthalmol 2022; http://dx.doi.org/10.1136/bjophthalmol-2021-320003
2. Sarma P, Kaur H, Kaur H, et al. Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID-19: a systematic review and meta-analysis. SSRN Electron J 2020; doi:10.2139/ssrn.3566161

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.